nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—CARTPT—prostate gland—urinary bladder cancer	0.0347	0.128	CbGeAlD
Amphetamine—TAAR1—female reproductive system—urinary bladder cancer	0.0189	0.0701	CbGeAlD
Amphetamine—CARTPT—female reproductive system—urinary bladder cancer	0.0189	0.0701	CbGeAlD
Amphetamine—SLC18A2—prostate gland—urinary bladder cancer	0.0118	0.0437	CbGeAlD
Amphetamine—CARTPT—lymph node—urinary bladder cancer	0.0111	0.041	CbGeAlD
Amphetamine—CYP2D6—urine—urinary bladder cancer	0.011	0.0406	CbGeAlD
Amphetamine—CYP2A6—prostate gland—urinary bladder cancer	0.0105	0.039	CbGeAlD
Amphetamine—Aspartame—TRPV1—urinary bladder cancer	0.00898	0.388	CrCbGaD
Amphetamine—CYP2A6—seminal vesicle—urinary bladder cancer	0.00889	0.033	CbGeAlD
Amphetamine—SLC22A3—prostate gland—urinary bladder cancer	0.00839	0.0311	CbGeAlD
Amphetamine—MAOB—prostate gland—urinary bladder cancer	0.00776	0.0288	CbGeAlD
Amphetamine—SLC22A3—seminal vesicle—urinary bladder cancer	0.00709	0.0263	CbGeAlD
Amphetamine—MAOB—seminal vesicle—urinary bladder cancer	0.00656	0.0243	CbGeAlD
Amphetamine—SLC18A2—female reproductive system—urinary bladder cancer	0.00643	0.0238	CbGeAlD
Amphetamine—SLC22A5—prostate gland—urinary bladder cancer	0.0061	0.0226	CbGeAlD
Amphetamine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00594	0.022	CbGeAlD
Amphetamine—SLC18A2—vagina—urinary bladder cancer	0.00581	0.0216	CbGeAlD
Amphetamine—SLC22A3—renal system—urinary bladder cancer	0.00572	0.0212	CbGeAlD
Amphetamine—SLC22A3—urethra—urinary bladder cancer	0.00561	0.0208	CbGeAlD
Amphetamine—Pseudoephedrine—IL2—urinary bladder cancer	0.00553	0.239	CrCbGaD
Amphetamine—MAOB—renal system—urinary bladder cancer	0.00529	0.0196	CbGeAlD
Amphetamine—MAOB—urethra—urinary bladder cancer	0.0052	0.0193	CbGeAlD
Amphetamine—CYP2A6—vagina—urinary bladder cancer	0.00519	0.0192	CbGeAlD
Amphetamine—SLC22A5—seminal vesicle—urinary bladder cancer	0.00516	0.0191	CbGeAlD
Amphetamine—Benzphetamine—POR—urinary bladder cancer	0.00492	0.213	CrCbGaD
Amphetamine—SLC22A3—female reproductive system—urinary bladder cancer	0.00458	0.017	CbGeAlD
Amphetamine—SLC6A4—female reproductive system—urinary bladder cancer	0.00446	0.0165	CbGeAlD
Amphetamine—MAOB—female reproductive system—urinary bladder cancer	0.00424	0.0157	CbGeAlD
Amphetamine—SLC22A5—renal system—urinary bladder cancer	0.00416	0.0154	CbGeAlD
Amphetamine—SLC22A3—vagina—urinary bladder cancer	0.00414	0.0154	CbGeAlD
Amphetamine—SLC22A5—urethra—urinary bladder cancer	0.00408	0.0151	CbGeAlD
Amphetamine—SLC6A2—female reproductive system—urinary bladder cancer	0.00392	0.0145	CbGeAlD
Amphetamine—MAOB—vagina—urinary bladder cancer	0.00383	0.0142	CbGeAlD
Amphetamine—SLC18A2—lymph node—urinary bladder cancer	0.00376	0.0139	CbGeAlD
Amphetamine—SLC22A5—female reproductive system—urinary bladder cancer	0.00333	0.0123	CbGeAlD
Amphetamine—SLC22A5—vagina—urinary bladder cancer	0.00301	0.0112	CbGeAlD
Amphetamine—CYP2D6—renal system—urinary bladder cancer	0.00268	0.00994	CbGeAlD
Amphetamine—SLC22A3—lymph node—urinary bladder cancer	0.00268	0.00993	CbGeAlD
Amphetamine—MAOB—lymph node—urinary bladder cancer	0.00248	0.00919	CbGeAlD
Amphetamine—SLC6A2—lymph node—urinary bladder cancer	0.00229	0.00851	CbGeAlD
Amphetamine—CYP2D6—female reproductive system—urinary bladder cancer	0.00215	0.00796	CbGeAlD
Amphetamine—SLC22A5—lymph node—urinary bladder cancer	0.00195	0.00722	CbGeAlD
Amphetamine—Pseudoephedrine—TNF—urinary bladder cancer	0.00187	0.0807	CrCbGaD
Amphetamine—Viral infection—Doxorubicin—urinary bladder cancer	0.00185	0.00446	CcSEcCtD
Amphetamine—Nateglinide—PPARG—urinary bladder cancer	0.00183	0.0792	CrCbGaD
Amphetamine—Agitation—Thiotepa—urinary bladder cancer	0.0018	0.00434	CcSEcCtD
Amphetamine—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00179	0.00432	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00179	0.00431	CcSEcCtD
Amphetamine—Dyskinesia—Doxorubicin—urinary bladder cancer	0.00178	0.00429	CcSEcCtD
Amphetamine—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.00178	0.00428	CcSEcCtD
Amphetamine—Myocardial infarction—Etoposide—urinary bladder cancer	0.00177	0.00426	CcSEcCtD
Amphetamine—Convulsion—Thiotepa—urinary bladder cancer	0.0017	0.00409	CcSEcCtD
Amphetamine—Hypertension—Thiotepa—urinary bladder cancer	0.0017	0.00408	CcSEcCtD
Amphetamine—Anxiety—Thiotepa—urinary bladder cancer	0.00167	0.00401	CcSEcCtD
Amphetamine—Infection—Thiotepa—urinary bladder cancer	0.00159	0.00383	CcSEcCtD
Amphetamine—Tachycardia—Thiotepa—urinary bladder cancer	0.00156	0.00376	CcSEcCtD
Amphetamine—Erythema multiforme—Etoposide—urinary bladder cancer	0.00153	0.00369	CcSEcCtD
Amphetamine—Anorexia—Thiotepa—urinary bladder cancer	0.00153	0.00368	CcSEcCtD
Amphetamine—Tremor—Cisplatin—urinary bladder cancer	0.00144	0.00347	CcSEcCtD
Amphetamine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.00143	0.00345	CcSEcCtD
Amphetamine—Hypertension—Gemcitabine—urinary bladder cancer	0.00143	0.00343	CcSEcCtD
Amphetamine—Somnolence—Thiotepa—urinary bladder cancer	0.00143	0.00343	CcSEcCtD
Amphetamine—Dyspepsia—Thiotepa—urinary bladder cancer	0.00141	0.0034	CcSEcCtD
Amphetamine—Convulsion—Fluorouracil—urinary bladder cancer	0.00141	0.00339	CcSEcCtD
Amphetamine—Chest pain—Gemcitabine—urinary bladder cancer	0.00141	0.00338	CcSEcCtD
Amphetamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.00139	0.00335	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00138	0.00333	CcSEcCtD
Amphetamine—Chest pain—Fluorouracil—urinary bladder cancer	0.00138	0.00333	CcSEcCtD
Amphetamine—Fatigue—Thiotepa—urinary bladder cancer	0.00138	0.00333	CcSEcCtD
Amphetamine—Constipation—Thiotepa—urinary bladder cancer	0.00137	0.0033	CcSEcCtD
Amphetamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00135	0.00324	CcSEcCtD
Amphetamine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00134	0.00322	CcSEcCtD
Amphetamine—Infection—Gemcitabine—urinary bladder cancer	0.00134	0.00322	CcSEcCtD
Amphetamine—Irritability—Methotrexate—urinary bladder cancer	0.00134	0.00322	CcSEcCtD
Amphetamine—Convulsion—Cisplatin—urinary bladder cancer	0.00133	0.00321	CcSEcCtD
Amphetamine—Mood swings—Methotrexate—urinary bladder cancer	0.00133	0.0032	CcSEcCtD
Amphetamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00133	0.00319	CcSEcCtD
Amphetamine—Infection—Fluorouracil—urinary bladder cancer	0.00132	0.00317	CcSEcCtD
Amphetamine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00131	0.00315	CcSEcCtD
Amphetamine—Anxiety—Cisplatin—urinary bladder cancer	0.00131	0.00314	CcSEcCtD
Amphetamine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.0013	0.00314	CcSEcCtD
Amphetamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00129	0.00311	CcSEcCtD
Amphetamine—Affect lability—Epirubicin—urinary bladder cancer	0.00129	0.00311	CcSEcCtD
Amphetamine—Anorexia—Gemcitabine—urinary bladder cancer	0.00129	0.00309	CcSEcCtD
Amphetamine—Urticaria—Thiotepa—urinary bladder cancer	0.00127	0.00306	CcSEcCtD
Amphetamine—Abdominal pain—Thiotepa—urinary bladder cancer	0.00127	0.00305	CcSEcCtD
Amphetamine—Body temperature increased—Thiotepa—urinary bladder cancer	0.00127	0.00305	CcSEcCtD
Amphetamine—Anorexia—Fluorouracil—urinary bladder cancer	0.00126	0.00304	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00126	0.00304	CcSEcCtD
Amphetamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00126	0.00302	CcSEcCtD
Amphetamine—Infection—Cisplatin—urinary bladder cancer	0.00125	0.003	CcSEcCtD
Amphetamine—Mood swings—Epirubicin—urinary bladder cancer	0.00124	0.00299	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00124	0.00298	CcSEcCtD
Amphetamine—Tachycardia—Cisplatin—urinary bladder cancer	0.00123	0.00295	CcSEcCtD
Amphetamine—Convulsion—Etoposide—urinary bladder cancer	0.00122	0.00294	CcSEcCtD
Amphetamine—Insomnia—Gemcitabine—urinary bladder cancer	0.00122	0.00293	CcSEcCtD
Amphetamine—Hypertension—Etoposide—urinary bladder cancer	0.00122	0.00293	CcSEcCtD
Amphetamine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00122	0.00292	CcSEcCtD
Amphetamine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.0012	0.00289	CcSEcCtD
Amphetamine—Chest pain—Etoposide—urinary bladder cancer	0.0012	0.00289	CcSEcCtD
Amphetamine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.0012	0.00289	CcSEcCtD
Amphetamine—Insomnia—Fluorouracil—urinary bladder cancer	0.0012	0.00289	CcSEcCtD
Amphetamine—Somnolence—Gemcitabine—urinary bladder cancer	0.0012	0.00288	CcSEcCtD
Amphetamine—Anorexia—Cisplatin—urinary bladder cancer	0.0012	0.00288	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—urinary bladder cancer	0.0012	0.00288	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00118	0.00285	CcSEcCtD
Amphetamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00118	0.00284	CcSEcCtD
Amphetamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00118	0.00284	CcSEcCtD
Amphetamine—Somnolence—Fluorouracil—urinary bladder cancer	0.00118	0.00284	CcSEcCtD
Amphetamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00117	0.00282	CcSEcCtD
Amphetamine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00117	0.00281	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00116	0.0028	CcSEcCtD
Amphetamine—Fatigue—Gemcitabine—urinary bladder cancer	0.00116	0.0028	CcSEcCtD
Amphetamine—Constipation—Gemcitabine—urinary bladder cancer	0.00115	0.00277	CcSEcCtD
Amphetamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00115	0.00277	CcSEcCtD
Amphetamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00115	0.00277	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—urinary bladder cancer	0.00115	0.00277	CcSEcCtD
Amphetamine—Asthenia—Thiotepa—urinary bladder cancer	0.00115	0.00277	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00114	0.00275	CcSEcCtD
Amphetamine—Infection—Etoposide—urinary bladder cancer	0.00114	0.00275	CcSEcCtD
Amphetamine—Tachycardia—Etoposide—urinary bladder cancer	0.00112	0.0027	CcSEcCtD
Amphetamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00112	0.0027	CcSEcCtD
Amphetamine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00112	0.00269	CcSEcCtD
Amphetamine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00111	0.00268	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00111	0.00267	CcSEcCtD
Amphetamine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00111	0.00266	CcSEcCtD
Amphetamine—Anorexia—Etoposide—urinary bladder cancer	0.0011	0.00264	CcSEcCtD
Amphetamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.0011	0.00264	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00109	0.00263	CcSEcCtD
Amphetamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00109	0.00263	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00109	0.00261	CcSEcCtD
Amphetamine—Depression—Methotrexate—urinary bladder cancer	0.00108	0.00259	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00107	0.00258	CcSEcCtD
Amphetamine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00107	0.00257	CcSEcCtD
Amphetamine—Dizziness—Thiotepa—urinary bladder cancer	0.00106	0.00255	CcSEcCtD
Amphetamine—Urticaria—Fluorouracil—urinary bladder cancer	0.00105	0.00253	CcSEcCtD
Amphetamine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00105	0.00252	CcSEcCtD
Amphetamine—Sweating—Methotrexate—urinary bladder cancer	0.00104	0.00249	CcSEcCtD
Amphetamine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00104	0.00249	CcSEcCtD
Amphetamine—Weight decreased—Epirubicin—urinary bladder cancer	0.00103	0.00247	CcSEcCtD
Amphetamine—Dyspnoea—Etoposide—urinary bladder cancer	0.00103	0.00247	CcSEcCtD
Amphetamine—Somnolence—Etoposide—urinary bladder cancer	0.00102	0.00246	CcSEcCtD
Amphetamine—Vomiting—Thiotepa—urinary bladder cancer	0.00102	0.00245	CcSEcCtD
Amphetamine—Rash—Thiotepa—urinary bladder cancer	0.00101	0.00243	CcSEcCtD
Amphetamine—Dermatitis—Thiotepa—urinary bladder cancer	0.00101	0.00243	CcSEcCtD
Amphetamine—Headache—Thiotepa—urinary bladder cancer	0.001	0.00242	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.001	0.00241	CcSEcCtD
Amphetamine—Decreased appetite—Etoposide—urinary bladder cancer	0.001	0.00241	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000994	0.00239	CcSEcCtD
Amphetamine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000994	0.00239	CcSEcCtD
Amphetamine—Fatigue—Etoposide—urinary bladder cancer	0.000993	0.00239	CcSEcCtD
Amphetamine—Constipation—Etoposide—urinary bladder cancer	0.000985	0.00237	CcSEcCtD
Amphetamine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000984	0.00237	CcSEcCtD
Amphetamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000977	0.00235	CcSEcCtD
Amphetamine—Sweating—Epirubicin—urinary bladder cancer	0.00097	0.00233	CcSEcCtD
Amphetamine—Asthenia—Gemcitabine—urinary bladder cancer	0.000967	0.00233	CcSEcCtD
Amphetamine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000959	0.00231	CcSEcCtD
Amphetamine—Nausea—Thiotepa—urinary bladder cancer	0.000952	0.00229	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—urinary bladder cancer	0.00095	0.00229	CcSEcCtD
Amphetamine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000942	0.00227	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000928	0.00223	CcSEcCtD
Amphetamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000926	0.00223	CcSEcCtD
Amphetamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000923	0.00222	CcSEcCtD
Amphetamine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000918	0.00221	CcSEcCtD
Amphetamine—Urticaria—Etoposide—urinary bladder cancer	0.000915	0.0022	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—urinary bladder cancer	0.00091	0.00219	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—urinary bladder cancer	0.00091	0.00219	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00091	0.00219	CcSEcCtD
Amphetamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000907	0.00218	CcSEcCtD
Amphetamine—Asthenia—Cisplatin—urinary bladder cancer	0.000902	0.00217	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—urinary bladder cancer	0.000898	0.00216	CcSEcCtD
Amphetamine—Dizziness—Fluorouracil—urinary bladder cancer	0.000877	0.00211	CcSEcCtD
Amphetamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00086	0.00207	CcSEcCtD
Amphetamine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000859	0.00207	CcSEcCtD
Amphetamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000857	0.00206	CcSEcCtD
Amphetamine—Rash—Gemcitabine—urinary bladder cancer	0.00085	0.00205	CcSEcCtD
Amphetamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000849	0.00204	CcSEcCtD
Amphetamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000848	0.00204	CcSEcCtD
Amphetamine—Headache—Gemcitabine—urinary bladder cancer	0.000845	0.00203	CcSEcCtD
Amphetamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000843	0.00203	CcSEcCtD
Amphetamine—Rash—Fluorouracil—urinary bladder cancer	0.000836	0.00201	CcSEcCtD
Amphetamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000835	0.00201	CcSEcCtD
Amphetamine—Headache—Fluorouracil—urinary bladder cancer	0.000831	0.002	CcSEcCtD
Amphetamine—Asthenia—Etoposide—urinary bladder cancer	0.000826	0.00199	CcSEcCtD
Amphetamine—Nausea—Gemcitabine—urinary bladder cancer	0.000801	0.00193	CcSEcCtD
Amphetamine—Vomiting—Cisplatin—urinary bladder cancer	0.000799	0.00192	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000795	0.00191	CcSEcCtD
Amphetamine—Rash—Cisplatin—urinary bladder cancer	0.000792	0.00191	CcSEcCtD
Amphetamine—Dermatitis—Cisplatin—urinary bladder cancer	0.000792	0.00191	CcSEcCtD
Amphetamine—Diarrhoea—Etoposide—urinary bladder cancer	0.000788	0.0019	CcSEcCtD
Amphetamine—Nausea—Fluorouracil—urinary bladder cancer	0.000788	0.0019	CcSEcCtD
Amphetamine—Tension—Epirubicin—urinary bladder cancer	0.000776	0.00187	CcSEcCtD
Amphetamine—Nervousness—Epirubicin—urinary bladder cancer	0.000768	0.00185	CcSEcCtD
Amphetamine—Dizziness—Etoposide—urinary bladder cancer	0.000761	0.00183	CcSEcCtD
Amphetamine—Nausea—Cisplatin—urinary bladder cancer	0.000747	0.0018	CcSEcCtD
Amphetamine—Convulsion—Methotrexate—urinary bladder cancer	0.000732	0.00176	CcSEcCtD
Amphetamine—Vomiting—Etoposide—urinary bladder cancer	0.000732	0.00176	CcSEcCtD
Amphetamine—Agitation—Epirubicin—urinary bladder cancer	0.000727	0.00175	CcSEcCtD
Amphetamine—Rash—Etoposide—urinary bladder cancer	0.000726	0.00175	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—urinary bladder cancer	0.000725	0.00175	CcSEcCtD
Amphetamine—Headache—Etoposide—urinary bladder cancer	0.000721	0.00174	CcSEcCtD
Amphetamine—Chest pain—Methotrexate—urinary bladder cancer	0.000719	0.00173	CcSEcCtD
Amphetamine—Tension—Doxorubicin—urinary bladder cancer	0.000718	0.00173	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—urinary bladder cancer	0.000711	0.00171	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—urinary bladder cancer	0.000699	0.00168	CcSEcCtD
Amphetamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00069	0.00166	CcSEcCtD
Amphetamine—Convulsion—Epirubicin—urinary bladder cancer	0.000685	0.00165	CcSEcCtD
Amphetamine—Infection—Methotrexate—urinary bladder cancer	0.000685	0.00165	CcSEcCtD
Amphetamine—Nausea—Etoposide—urinary bladder cancer	0.000684	0.00165	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—urinary bladder cancer	0.000683	0.00164	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—GSTM1—urinary bladder cancer	0.00068	0.00233	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—NQO1—urinary bladder cancer	0.000676	0.00232	CbGpPWpGaD
Amphetamine—Chest pain—Epirubicin—urinary bladder cancer	0.000673	0.00162	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—urinary bladder cancer	0.000672	0.00162	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—urinary bladder cancer	0.000671	0.00161	CcSEcCtD
Amphetamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000667	0.0016	CcSEcCtD
Amphetamine—SLC6A3—Monoamine Transport—TNF—urinary bladder cancer	0.000664	0.00228	CbGpPWpGaD
Amphetamine—Dry mouth—Epirubicin—urinary bladder cancer	0.000658	0.00158	CcSEcCtD
Amphetamine—Anorexia—Methotrexate—urinary bladder cancer	0.000657	0.00158	CcSEcCtD
Amphetamine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000647	0.00222	CbGpPWpGaD
Amphetamine—Palpitations—Doxorubicin—urinary bladder cancer	0.000647	0.00156	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000645	0.00155	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000643	0.0022	CbGpPWpGaD
Amphetamine—Infection—Epirubicin—urinary bladder cancer	0.000641	0.00154	CcSEcCtD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000641	0.0022	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000639	0.00219	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000636	0.00218	CbGpPWpGaD
Amphetamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000634	0.00153	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000632	0.00152	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—urinary bladder cancer	0.00063	0.00152	CcSEcCtD
Amphetamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000624	0.0015	CcSEcCtD
Amphetamine—Insomnia—Methotrexate—urinary bladder cancer	0.000624	0.0015	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—urinary bladder cancer	0.000623	0.0015	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—urinary bladder cancer	0.000621	0.00149	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—urinary bladder cancer	0.000615	0.00148	CcSEcCtD
Amphetamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000615	0.00148	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	0.000614	0.00211	CbGpPWpGaD
Amphetamine—Somnolence—Methotrexate—urinary bladder cancer	0.000613	0.00148	CcSEcCtD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000613	0.0021	CbGpPWpGaD
Amphetamine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000609	0.00147	CcSEcCtD
Amphetamine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000607	0.00146	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000606	0.00208	CbGpPWpGaD
Amphetamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.0006	0.00144	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000597	0.00205	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000597	0.00144	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	0.000596	0.00204	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000595	0.00143	CcSEcCtD
Amphetamine—Fatigue—Methotrexate—urinary bladder cancer	0.000595	0.00143	CcSEcCtD
Amphetamine—Infection—Doxorubicin—urinary bladder cancer	0.000593	0.00143	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000585	0.002	CbGpPWpGaD
Amphetamine—Insomnia—Epirubicin—urinary bladder cancer	0.000584	0.0014	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000583	0.0014	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000577	0.00139	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000575	0.00138	CcSEcCtD
Amphetamine—Somnolence—Epirubicin—urinary bladder cancer	0.000574	0.00138	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000569	0.00137	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000568	0.00137	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	0.000564	0.00194	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000564	0.00136	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—GSTP1—urinary bladder cancer	0.000564	0.00193	CbGpPWpGaD
Amphetamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000561	0.00135	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000557	0.00134	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—urinary bladder cancer	0.000556	0.00134	CcSEcCtD
Amphetamine—Constipation—Epirubicin—urinary bladder cancer	0.000552	0.00133	CcSEcCtD
Amphetamine—Urticaria—Methotrexate—urinary bladder cancer	0.000548	0.00132	CcSEcCtD
Amphetamine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000545	0.00131	CcSEcCtD
Amphetamine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000545	0.00131	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—urinary bladder cancer	0.00054	0.0013	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000533	0.00183	CbGpPWpGaD
Amphetamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000532	0.00128	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—urinary bladder cancer	0.000531	0.00128	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.00053	0.00182	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000528	0.00127	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000526	0.00181	CbGpPWpGaD
Amphetamine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000526	0.00127	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000524	0.0018	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000522	0.00179	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTZ1—urinary bladder cancer	0.000519	0.00178	CbGpPWpGaD
Amphetamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000519	0.00125	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—GSTM1—urinary bladder cancer	0.000518	0.00178	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000516	0.00124	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—urinary bladder cancer	0.000515	0.00124	CcSEcCtD
Amphetamine—Urticaria—Epirubicin—urinary bladder cancer	0.000513	0.00123	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—urinary bladder cancer	0.000511	0.00123	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—urinary bladder cancer	0.00051	0.00123	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—urinary bladder cancer	0.00051	0.00123	CcSEcCtD
Amphetamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000508	0.00122	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—GLI1—urinary bladder cancer	0.000501	0.00172	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.0005	0.00172	CbGpPWpGaD
Amphetamine—Asthenia—Methotrexate—urinary bladder cancer	0.000495	0.00119	CcSEcCtD
Amphetamine—MAOB—Metabolism—GSTO2—urinary bladder cancer	0.000492	0.00169	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NAT1—urinary bladder cancer	0.000492	0.00169	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000488	0.00118	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000477	0.00164	CbGpPWpGaD
Amphetamine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000476	0.00114	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—urinary bladder cancer	0.000474	0.00114	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000472	0.00114	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000472	0.00114	CcSEcCtD
Amphetamine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000472	0.00114	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—FAS—urinary bladder cancer	0.000472	0.00162	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	0.000471	0.00161	CbGpPWpGaD
Amphetamine—Asthenia—Epirubicin—urinary bladder cancer	0.000463	0.00111	CcSEcCtD
Amphetamine—Dizziness—Methotrexate—urinary bladder cancer	0.000456	0.0011	CcSEcCtD
Amphetamine—MAOB—Metabolism—UGT2B7—urinary bladder cancer	0.00045	0.00154	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000444	0.00152	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000443	0.00152	CbGpPWpGaD
Amphetamine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000442	0.00106	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00044	0.00106	CcSEcCtD
Amphetamine—SLC22A3—Metabolism—GSTZ1—urinary bladder cancer	0.000439	0.00151	CbGpPWpGaD
Amphetamine—Vomiting—Methotrexate—urinary bladder cancer	0.000439	0.00106	CcSEcCtD
Amphetamine—Rash—Methotrexate—urinary bladder cancer	0.000435	0.00105	CcSEcCtD
Amphetamine—Dermatitis—Methotrexate—urinary bladder cancer	0.000434	0.00105	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	0.000433	0.00148	CbGpPWpGaD
Amphetamine—Headache—Methotrexate—urinary bladder cancer	0.000432	0.00104	CcSEcCtD
Amphetamine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000431	0.00148	CbGpPWpGaD
Amphetamine—Asthenia—Doxorubicin—urinary bladder cancer	0.000428	0.00103	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—urinary bladder cancer	0.000427	0.00103	CcSEcCtD
Amphetamine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000425	0.00146	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTO2—urinary bladder cancer	0.000416	0.00143	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NAT1—urinary bladder cancer	0.000416	0.00143	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000415	0.00142	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000413	0.00142	CbGpPWpGaD
Amphetamine—Vomiting—Epirubicin—urinary bladder cancer	0.00041	0.000988	CcSEcCtD
Amphetamine—Nausea—Methotrexate—urinary bladder cancer	0.00041	0.000986	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000409	0.0014	CbGpPWpGaD
Amphetamine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000409	0.000983	CcSEcCtD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000408	0.0014	CbGpPWpGaD
Amphetamine—Rash—Epirubicin—urinary bladder cancer	0.000407	0.000979	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—urinary bladder cancer	0.000407	0.000978	CcSEcCtD
Amphetamine—MAOB—Metabolism—CYP4B1—urinary bladder cancer	0.000405	0.00139	CbGpPWpGaD
Amphetamine—Headache—Epirubicin—urinary bladder cancer	0.000404	0.000973	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000403	0.00138	CbGpPWpGaD
Amphetamine—Dizziness—Doxorubicin—urinary bladder cancer	0.000395	0.00095	CcSEcCtD
Amphetamine—Nausea—Epirubicin—urinary bladder cancer	0.000383	0.000923	CcSEcCtD
Amphetamine—MAOB—Metabolism—SLC19A1—urinary bladder cancer	0.000383	0.00131	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—UGT2B7—urinary bladder cancer	0.000381	0.00131	CbGpPWpGaD
Amphetamine—Vomiting—Doxorubicin—urinary bladder cancer	0.00038	0.000914	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000379	0.0013	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000377	0.00129	CbGpPWpGaD
Amphetamine—Rash—Doxorubicin—urinary bladder cancer	0.000377	0.000906	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000376	0.000905	CcSEcCtD
Amphetamine—Headache—Doxorubicin—urinary bladder cancer	0.000374	0.0009	CcSEcCtD
Amphetamine—MAOB—Metabolism—PRSS3—urinary bladder cancer	0.000373	0.00128	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000361	0.00124	CbGpPWpGaD
Amphetamine—Nausea—Doxorubicin—urinary bladder cancer	0.000355	0.000854	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000354	0.00121	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000353	0.00121	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000352	0.00121	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000344	0.00118	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RBX1—urinary bladder cancer	0.000343	0.00118	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP4B1—urinary bladder cancer	0.000343	0.00118	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000334	0.00115	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000326	0.00112	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC19A1—urinary bladder cancer	0.000324	0.00111	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TSC1—urinary bladder cancer	0.000323	0.00111	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000322	0.0011	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PRSS3—urinary bladder cancer	0.000316	0.00108	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000307	0.00105	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000302	0.00104	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TYMP—urinary bladder cancer	0.000298	0.00102	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—FAS—urinary bladder cancer	0.000289	0.00099	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000275	0.000944	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NAT2—urinary bladder cancer	0.00027	0.000925	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.00026	0.00089	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000259	0.000887	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000254	0.000871	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.000253	0.000867	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TYMP—urinary bladder cancer	0.000252	0.000865	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—S100B—urinary bladder cancer	0.000249	0.000853	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—EP300—urinary bladder cancer	0.000247	0.000846	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000245	0.000841	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000244	0.000837	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	0.00024	0.000822	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NAT1—urinary bladder cancer	0.00024	0.000822	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000236	0.000809	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—RRM2—urinary bladder cancer	0.000233	0.000798	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000232	0.000794	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000231	0.000791	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000228	0.000783	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NAT2—urinary bladder cancer	0.000228	0.000782	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000228	0.000782	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000224	0.000767	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	0.000219	0.000752	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000218	0.000747	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000217	0.000743	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ENO2—urinary bladder cancer	0.000216	0.000739	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HPGDS—urinary bladder cancer	0.000216	0.000739	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000213	0.00073	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00021	0.00072	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTT1—urinary bladder cancer	0.000209	0.000717	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000207	0.00071	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL2—urinary bladder cancer	0.000198	0.000678	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	0.000197	0.000677	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TERT—urinary bladder cancer	0.000197	0.000676	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—RRM2—urinary bladder cancer	0.000197	0.000675	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000192	0.000657	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	0.000186	0.000639	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ENO2—urinary bladder cancer	0.000182	0.000626	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HPGDS—urinary bladder cancer	0.000182	0.000626	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	0.000182	0.000623	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FGFR3—urinary bladder cancer	0.000181	0.00062	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTT1—urinary bladder cancer	0.000177	0.000607	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	0.000177	0.000606	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ESR1—urinary bladder cancer	0.000176	0.000602	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NQO1—urinary bladder cancer	0.000174	0.000596	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—HRAS—urinary bladder cancer	0.000166	0.000569	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000166	0.000568	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000165	0.000566	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000158	0.000543	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000155	0.000533	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CREBBP—urinary bladder cancer	0.000154	0.000528	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1—urinary bladder cancer	0.000152	0.000521	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EGFR—urinary bladder cancer	0.000151	0.000519	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—EP300—urinary bladder cancer	0.000151	0.000518	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NQO1—urinary bladder cancer	0.000147	0.000504	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TYMP—urinary bladder cancer	0.000145	0.000498	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTP1—urinary bladder cancer	0.000145	0.000497	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—urinary bladder cancer	0.000143	0.00049	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000142	0.000486	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC4—urinary bladder cancer	0.000139	0.000478	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RHOA—urinary bladder cancer	0.000139	0.000478	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TYMS—urinary bladder cancer	0.000135	0.000462	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000134	0.000461	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000134	0.000461	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTM1—urinary bladder cancer	0.000133	0.000457	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NCOR1—urinary bladder cancer	0.000133	0.000457	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NAT2—urinary bladder cancer	0.000131	0.000451	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000129	0.000443	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—urinary bladder cancer	0.000129	0.000442	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000129	0.000442	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GPX1—urinary bladder cancer	0.000128	0.000437	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ERCC2—urinary bladder cancer	0.000125	0.000429	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000124	0.000424	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000123	0.000422	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTP1—urinary bladder cancer	0.000123	0.000421	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—urinary bladder cancer	0.000122	0.000419	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—urinary bladder cancer	0.000121	0.000417	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTHFR—urinary bladder cancer	0.000118	0.000404	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—urinary bladder cancer	0.000117	0.000401	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GLI1—urinary bladder cancer	0.000117	0.0004	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000114	0.000392	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TYMS—urinary bladder cancer	0.000114	0.000391	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—urinary bladder cancer	0.000114	0.000391	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—RRM2—urinary bladder cancer	0.000113	0.000389	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—urinary bladder cancer	0.000113	0.000386	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NCOR1—urinary bladder cancer	0.000113	0.000386	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000111	0.00038	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—urinary bladder cancer	0.000111	0.000379	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1A—urinary bladder cancer	0.00011	0.000378	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—urinary bladder cancer	0.00011	0.000377	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—urinary bladder cancer	0.000108	0.000371	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GPX1—urinary bladder cancer	0.000108	0.00037	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ERCC2—urinary bladder cancer	0.000106	0.000363	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	0.000105	0.00036	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO2—urinary bladder cancer	0.000105	0.00036	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EP300—urinary bladder cancer	0.000105	0.00036	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000105	0.000359	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SRC—urinary bladder cancer	0.000102	0.00035	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000102	0.000349	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	0.000102	0.000349	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—urinary bladder cancer	9.96e-05	0.000342	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	9.9e-05	0.000339	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—urinary bladder cancer	9.55e-05	0.000327	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—urinary bladder cancer	9.41e-05	0.000323	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CREBBP—urinary bladder cancer	9.17e-05	0.000314	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—urinary bladder cancer	9.14e-05	0.000313	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—urinary bladder cancer	8.94e-05	0.000306	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NQO1—urinary bladder cancer	8.47e-05	0.00029	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—urinary bladder cancer	8.44e-05	0.00029	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	8.15e-05	0.000279	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—urinary bladder cancer	8.08e-05	0.000277	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RBX1—urinary bladder cancer	8e-05	0.000274	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CREBBP—urinary bladder cancer	7.76e-05	0.000266	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSC1—urinary bladder cancer	7.52e-05	0.000258	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—urinary bladder cancer	7.51e-05	0.000257	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—urinary bladder cancer	7.5e-05	0.000257	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	7.37e-05	0.000253	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—urinary bladder cancer	7.18e-05	0.000246	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JAG1—urinary bladder cancer	7.16e-05	0.000246	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	7.06e-05	0.000242	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TYMS—urinary bladder cancer	6.56e-05	0.000225	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—urinary bladder cancer	6.55e-05	0.000225	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	6.49e-05	0.000223	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	6.49e-05	0.000223	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	6.36e-05	0.000218	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—urinary bladder cancer	6.35e-05	0.000218	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—EP300—urinary bladder cancer	6.24e-05	0.000214	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPX1—urinary bladder cancer	6.21e-05	0.000213	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	6.1e-05	0.000209	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—RHOA—urinary bladder cancer	6.06e-05	0.000208	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.89e-05	0.000202	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.89e-05	0.000202	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—S100B—urinary bladder cancer	5.8e-05	0.000199	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	5.73e-05	0.000197	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	5.71e-05	0.000196	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—urinary bladder cancer	5.54e-05	0.00019	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RHOA—urinary bladder cancer	5.5e-05	0.000189	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.32e-05	0.000182	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—EP300—urinary bladder cancer	5.28e-05	0.000181	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	5.22e-05	0.000179	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	5.08e-05	0.000174	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	4.83e-05	0.000166	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.75e-05	0.000163	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—urinary bladder cancer	4.65e-05	0.000159	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	4.61e-05	0.000158	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—urinary bladder cancer	4.6e-05	0.000158	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	4.47e-05	0.000153	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	4.22e-05	0.000145	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	4.1e-05	0.00014	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.96e-05	0.000136	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.68e-05	0.000126	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	3.66e-05	0.000125	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.64e-05	0.000125	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.64e-05	0.000125	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	3.59e-05	0.000123	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	3.55e-05	0.000122	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	3.53e-05	0.000121	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.48e-05	0.000119	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.42e-05	0.000117	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	3.33e-05	0.000114	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	3.25e-05	0.000111	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.22e-05	0.00011	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	3.19e-05	0.000109	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—EP300—urinary bladder cancer	3.04e-05	0.000104	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	3.01e-05	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	2.85e-05	9.78e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	2.83e-05	9.72e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	2.73e-05	9.35e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	2.66e-05	9.11e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.61e-05	8.94e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	2.58e-05	8.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.57e-05	8.81e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	2.56e-05	8.79e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.5e-05	8.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	2.45e-05	8.39e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	2.38e-05	8.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	2.13e-05	7.31e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-05	7.15e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.05e-05	7.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.97e-05	6.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.79e-05	6.13e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	1.75e-05	6e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.71e-05	5.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-05	5.74e-05	CbGpPWpGaD
